TABLE 2.
Correlation between immunological response and overall response rate (full analysis set) in patients with advanced solid tumors treated with cancer peptide vaccine TAS0313
| Dose (mg) | Patient | Cancer | HLA‐A | IgG a | CTL b | TIL c | Antigen d | ORR |
|---|---|---|---|---|---|---|---|---|
| 9 | 1 | Biliary tract | 24 | + | − | ND | 8 | PD |
| 2 | Breast | 11 | + | − | ND | ND | PD | |
| 3 | Lung | 02 | + | − | ND | 7 | PD | |
| 4 | Carcinoma of unknown primary | 24 | + | + | ND | ND | SD | |
| 5 | Ovary | 11 | − | − | ND | ND | PD | |
| 6 | Pancreas | 24, 31 | + | − | ND | ND | PD | |
| 7 | Gall bladder | 02, 24 | + | + | − | 8 | PD | |
| 8 | Pancreas | 02, 24 | + | − | + | 8 | PD | |
| 9 | Pancreas | 24, 31 | + | − | ND | 8 | PD | |
| 10 | Retiform hemangioendothelioma | 02, 24 | + | − | + | 8 | SD | |
| 27 | 1 | Palatal gingiva cancer | 31, 33 | + | − | − | 8 | SD |
| 2 | Biliary tract | 24 | + | + | ND | 8 | PD | |
| 3 | Pancreas | 02 | + | − | ND | 7 | SD | |
| 4 | Lung | 11, 24 | + | + | + | 8 | PD | |
| 5 | Gall bladder | 02, 24 | + | + | ND | 8 | PD | |
| 6 | Duodenal papilla neuroendocrine carcinoma | 11, 31 | + | − | + | 8 | PD | |
| 7 | Peritoneum mesothelioma | 24, 33 | + | − | + | 8 | PD |
Abbreviations: HLA, human leukocyte antigen; ND, not determined (samples unavailable); ORR, overall response rate; PD, progressive disease; SD, stable disease; TIL, tumor‐infiltrating lymphocyte.
a
At least one IgG level was ≥30%, compared with baseline.
b
≥250 spots/100 000 cells.
c
Increased by 1 or more compared with baseline.
d
Target cancer‐associated antigen expression‐positive number out of eight antigens (Table S5).